Skip to search formSkip to main contentSkip to account menu

lorlatinib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A significant subset of patients with non–small-cell lung cancer (NSCLC) harbor activating mutations in key oncogenes like EGFR… 
2019
2019
The tyrosine-kinase inhibitors (TKIs) crizotinib and entrectinib have been approved by the FDA for the treatment of ROS1-positive… 
2018
2018
BACKGROUND: Lorlatinib is a selective, potent, brain-penetrant, 3rd-generation ALK/ROS1 TKI preclinically active against most… 
2018
2018
In the last decade huge improvements in prognosis and quality of life have been provided by the molecular characterization of… 
2017
2017
Patients with lung cancer who show EML4-ALK translocation are routinely treated with ALK tyrosine kinase inhibitors, although in… 
2016
2016
Data from a phase I study indicate that the investigational ALK inhibitor lorlatinib is active in patients with ALK- or ROS1… 
2015
2015
ALK-positive Anaplastic Large Cell Lymphoma (ALCL) represents a subset of Non-Hodgkin Lymphoma whose treatment benefited from…